Kaveri Pohlman
Stock Analyst at Clear Street
(0.18)
# 4,280
Out of 4,944 analysts
22
Total ratings
14.29%
Success rate
-32.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kaveri Pohlman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVBP ArriVent BioPharma | Initiates: Buy | $32 | $18.05 | +77.33% | 1 | Jun 25, 2025 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $1.66 | - | 4 | Aug 1, 2024 | |
| GMAB Genmab | Maintains: Buy | $46 → $47 | $22.67 | +107.32% | 3 | Jun 27, 2024 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $20 → $30 | $7.64 | +292.67% | 2 | Apr 17, 2024 | |
| XNCR Xencor | Maintains: Buy | $56 → $38 | $7.72 | +392.23% | 1 | Apr 16, 2024 | |
| NUVB Nuvation Bio | Upgrades: Buy | $5 | $2.61 | +91.57% | 2 | Mar 26, 2024 | |
| JANX Janux Therapeutics | Initiates: Buy | $62 | $24.96 | +148.40% | 1 | Mar 21, 2024 | |
| PYXS Pyxis Oncology | Initiates: Buy | $8 | $1.07 | +647.66% | 1 | Feb 9, 2024 | |
| EXEL Exelixis | Initiates: Buy | $27 | $38.49 | -29.85% | 1 | Dec 19, 2023 | |
| RCUS Arcus Biosciences | Reiterates: Buy | $70 | $10.06 | +595.83% | 1 | Aug 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.81 | +1,380.20% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $8 | $1.78 | +350.70% | 2 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12,320 → $4,928 | $3.95 | +124,659.49% | 2 | Feb 9, 2022 |
ArriVent BioPharma
Jun 25, 2025
Initiates: Buy
Price Target: $32
Current: $18.05
Upside: +77.33%
MacroGenics
Aug 1, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.66
Upside: -
Genmab
Jun 27, 2024
Maintains: Buy
Price Target: $46 → $47
Current: $22.67
Upside: +107.32%
Cullinan Therapeutics
Apr 17, 2024
Maintains: Buy
Price Target: $20 → $30
Current: $7.64
Upside: +292.67%
Xencor
Apr 16, 2024
Maintains: Buy
Price Target: $56 → $38
Current: $7.72
Upside: +392.23%
Nuvation Bio
Mar 26, 2024
Upgrades: Buy
Price Target: $5
Current: $2.61
Upside: +91.57%
Janux Therapeutics
Mar 21, 2024
Initiates: Buy
Price Target: $62
Current: $24.96
Upside: +148.40%
Pyxis Oncology
Feb 9, 2024
Initiates: Buy
Price Target: $8
Current: $1.07
Upside: +647.66%
Exelixis
Dec 19, 2023
Initiates: Buy
Price Target: $27
Current: $38.49
Upside: -29.85%
Arcus Biosciences
Aug 23, 2023
Reiterates: Buy
Price Target: $70
Current: $10.06
Upside: +595.83%
Aug 31, 2022
Initiates: Buy
Price Target: $12
Current: $0.81
Upside: +1,380.20%
Jul 7, 2022
Maintains: Buy
Price Target: $16 → $8
Current: $1.78
Upside: +350.70%
Feb 9, 2022
Maintains: Buy
Price Target: $12,320 → $4,928
Current: $3.95
Upside: +124,659.49%